Gamida Cell
Gamida Cell Ltd. is a commercial-stage biopharmaceutical company developing and commercializing FDA-approved cell therapies (Omisirge) and stem cell mobilization agents (APHEXDA) for hematologic malignancies, severe aplastic anemia, and multiple myeloma patients requiring transplantation, sold primarily to US transplant centers and via international distribution partners.
- Company typePrivate
- Founded2001
- HeadquartersJerusalem, Israel
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gamida Cell does
Gamida Cell Ltd. is a commercial-stage biopharmaceutical company headquartered in Jerusalem, Israel, with US commercial operations based in Naples, Florida, and a wholly owned GMP manufacturing facility in Kiryat Gat, Israel. Founded in 2001 (incorporated as a subsidiary operating under parent Ayrmid Ltd., a UK entity, since November 2024), the company develops and commercializes cell therapies and adjunctive products for hematologic malignancies, severe aplastic anemia, and stem cell transplantation. Its core commercial products are Omisirge (Omidubicel-onlv), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood and FDA-approved for hematologic malignancies (May 2023) and severe aplastic anemia (December 2025), and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization in multiple myeloma, in-licensed from BioLineRx in November 2024.
The company is built around a proprietary nicotinamide (NAM) cell-expansion platform that enhances and expands stem cells while preserving intrinsic functional properties such as homing, retention in bone marrow, and metabolic fitness. This platform underpins Omisirge and supports the company's positioning in the allogeneic transplant market, where it addresses patients who lack a matched donor. Business model revenue comes from one-time product sales of FDA-approved cell therapies and mobilization agents to US transplant centers via a direct specialty field-sales organization, supplemented by international distribution partnerships (ACA Pharma covering 15 Greater China and Southeast Asia markets; Ariti S.A. for Greece and Cyprus) and licensing royalties. Patient support is delivered through the Gamida Cell Assist program, which provides enrollment, order tracking, reimbursement, and financial assistance services. A new US manufacturing partnership with RoslinCT (Hopkinton, MA) is being established to supply Omisirge commercially beginning in 2027.
Gamida Cell firmographics
Firmographics- Name
- Gamida Cell
- Legal name
- Gamida Cell Ltd.
- Website
- https://gamida-cell.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Gamida Cell Ltd. is a commercial-stage biopharmaceutical company developing and commercializing FDA-approved cell therapies (Omisirge) and stem cell mobilization agents (APHEXDA) for hematologic malignancies, severe aplastic anemia, and multiple myeloma patients requiring transplantation, sold primarily to US transplant centers and via international distribution partners.
- Ownership category
- akta.pro rank
Gamida Cell industry classification
Industry- Product category
- Cell Therapy Pharmaceuticals
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Hematologic Oncology (Leukemia/Lymphoma/Myeloma) (HLAKAFAD)
Keywords
Where Gamida Cell is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
Gamida Cell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Omisirge Sales: Revenue from sales of Omisirge (Omidubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy for patients requiring stem cell transplant. Marketed to transplant centers and hospitals in the US.
- APHEXDA Sales: Revenue from sales of APHEXDA (motixafortide), an FDA-approved CXCR4 antagonist for stem cell mobilization in multiple myeloma. Licensed from BioLineRx for commercialization in all territories excluding solid tumors and Asia.
- International Distribution Royalties: Revenue from international distribution partnerships including Ayrmid's agreements with ACA Pharma for Greater China/Southeast Asia and Ariti for Greece/Cyprus.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Gamida Cell product offering
Product offeringCore offering
Gamida Cell develops and commercializes cell therapies for patients with blood cancers and serious hematologic diseases. Its commercial products include Omisirge (omidoubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma. The company also operates the Gamida Cell Assist patient support program and conducts ongoing clinical development for severe aplastic anemia and sickle cell disease indications.
Product overview
Gamida Cell offers a focused portfolio of FDA-approved cell therapy products for hematologic conditions. The core products are Omisirge (Omidubicel onlv), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood, and APHEXDA (motixafortide), a CXCR4 antagonist for stem cell mobilization in multiple myeloma. These are complemented by Gamida Cell Assist, a patient support services program. The company leverages its proprietary nicotinamide (NAM) technology to enhance and expand stem cells while maintaining their intrinsic properties.
Differentiator
Problem solved
Functional benefit
Brands
- APHEXDA (motixafortide): FDA-approved CXCR4 antagonist indicated in combination with filgrastim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.
- Gamida Cell Assist
Products and services
- Omisirge (omidoubicel-onlv)
Quantifiable outcome
- Median time to neutrophil recovery: 8-11 days in SAA patients
- +6 more outcomes
Companies that use Gamida Cell
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles1 record
Gamida Cell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Gamida Cell partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- American Biotech Innovation Alliance (ABIA)minorGamida Cell is a member company of ABIA, a new coalition of approximately 50 biotechnology companies formed to develop a national policy strategy to strengthen American biotech innovation amid rising competition from China.
- ACA PharmacoreExclusive distributor appointed for Omisirge across 15 markets in Greater China and Southeast Asia including Mainland China, Hong Kong, Singapore, Vietnam, and Indonesia. ACA Pharma holds exclusive rights to register and distribute the therapy.
- Ariti S.A.coreExclusive distribution agreement with Greece-based pharmaceutical company Ariti S.A. for distribution of Omisirge in Greece and Cyprus. Ariti will leverage its local market infrastructure and hematology expertise to support early access schemes.
- BioLineRxcoreExclusive license agreement for Ayrmid/Gamida Cell to commercialize APHEXDA (motixafortide) across all indications excluding solid tumors and all territories other than Asia. BioLineRx received $10 million upfront payment plus up to $87 million in commercial milestones and 18-23% royalties on net sales.
- RoslinCTcoreStrategic manufacturing partnership for future production of Omisirge in the US. Technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art cell therapy CGMP manufacturing facility in Hopkinton, MA beginning in 2027.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Gamida Cell competitors and assessment
Company assessmentDirect peers
- Allogene Therapeutics: Allogene Therapeutics is a clinical-stage allogeneic CAR-T developer targeting hematologic malignancies with off-the-shelf cell therapy products, directly comparable to Gamida Cell's allogeneic, off-the-shelf Omisirge approach in blood cancers.
- Iovance Biotherapeutics: Iovance commercializes cell therapies for hematologic and solid tumors and represents a leading direct peer in the cell therapy commercialization space, operating in the same disease setting (hematologic malignancies) as Gamida Cell.
- Fate Therapeutics: Fate Therapeutics develops off-the-shelf, iPSC-derived cell therapies for cancer and immune disorders, sharing Gamida Cell's allogeneic, off-the-shelf cell therapy philosophy and heme-oncology focus.
- Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell therapies (SPEAR T-cells) for hematologic malignancies and solid tumors, overlapping with Gamida Cell's cell therapy approach to blood cancer treatment.
- Mesoblast: Mesoblast develops allogeneic cellular medicines (remestemcel-L) for inflammatory and hematologic conditions including pediatric steroid-refractory acute graft-versus-host disease, a direct peer in the allogeneic cell therapy for hematologic disease space.
Broad incumbents
- Kite Pharma (Gilead): Kite Pharma, a Gilead subsidiary, markets Yescarta and Tecartus autologous CAR-T therapies for lymphoma/leukemia, representing a broader incumbent cell therapy player whose commercial CAR-T products compete for the same hematologic transplant patient pool served by Omisirge.
- Bristol Myers Squibb (Cell Therapy): BMS markets Breyanzi and Abecma CAR-T cell therapies for lymphoma and multiple myeloma, positioning it as a broad incumbent cell therapy competitor alongside Gamida Cell in hematologic malignancies and multiple myeloma.
- Novartis (Kymriah): Novartis commercializes the first FDA-approved CAR-T Kymriah for pediatric/young adult ALL and DLBCL, an established broad incumbent cell therapy player whose autologous CAR-T competes with Gamida Cell's allogeneic Omisirge in similar indications.
Emerging players
- CRISPR Therapeutics: CRISPR Therapeutics co-developed Casgevy, the first FDA-approved CRISPR gene therapy for sickle cell disease, where motixafortide/APHEXDA serves as a stem cell mobilization enabler—creating a complementary commercial relationship relevant to Gamida Cell's APHEXDA.
- Bluebird Bio: Bluebird bio develops gene and cell therapies for severe genetic diseases including sickle cell (Lyfgenia); although focused on gene-modified approaches, its commercial launch in sickle cell directly drives demand for stem cell mobilization agents like APHEXDA.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Gamida Cell social profiles
Digital presenceGamida Cell compliance and trust
Trust signalCompliance1 record
Gamida Cell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gamida Cell leadership team
Management profileNumber of profiles
Profiles15 records
Gamida Cell subsidiaries and ownership
Company hierarchySubsidiaries2 records
Gamida Cell funding detail
Funding detailFunding overview
Funding rounds13 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gamida Cell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gamida Cell
What does Gamida Cell do?
Gamida Cell develops and commercializes cell therapies for patients with blood cancers and serious hematologic diseases. Its commercial products include Omisirge (omidoubicel-onlv), an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, and APHEXDA (motixafortide), a CXCR4 antagonist for hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma. The company also operates the Gamida Cell Assist patient support program and conducts ongoing clinical development for severe aplastic anemia and sickle cell disease indications.
Is Gamida Cell a public or private company?
Gamida Cell is a private company. It is classified as corporate owned and is currently operating.
When was Gamida Cell founded?
Gamida Cell was founded in 2001. It employs 101 to 250 people.
Where is Gamida Cell based?
Gamida Cell is headquartered in Jerusalem, Israel, in the Middle East region.
How does Gamida Cell make money?
Three revenue lines are on record. Omisirge Sales are the primary driver. The others are APHEXDA Sales and international Distribution Royalties.
Who are Gamida Cell's main competitors?
Direct peers on record are Allogene Therapeutics, Iovance Biotherapeutics, Fate Therapeutics, Adaptimmune Therapeutics and Mesoblast. Broad incumbents are Kite Pharma (Gilead), Bristol Myers Squibb (Cell Therapy) and Novartis (Kymriah). Emerging players are CRISPR Therapeutics and Bluebird Bio.
Does Gamida Cell have an API?
No public API is recorded for Gamida Cell.
What industry is Gamida Cell in?
Gamida Cell's product category is Cell Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 621991 and its SIC code is 2836.